Tag: Aquavit Pharmaceuticals

All

Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.

Researchers found participation among underrepresented racial and ethnic groups increased far beyond national population growth.